The researchers at New England Journal of Medicine have found Sotorasib to be safe having clinical benefit in non-small cell lung cancer (NSCLC). The results of the study were presented at the virtual meeting of the European Society for Medical Oncology and involved 129 patients with KRAS-mutated cancers, including NSCLC. Three-quarters of these had tried